“That was an interesting welcome to federal service,” Ned Sharpless told me when I asked him about how he handled his first government shutdown.
You see, Sharpless became director of the National Cancer Institute, part of the National Institutes of Health, in mid-October. At that time, I thought it would be good to conduct a video interview with him because … well … he’s theNCI director. But I agreed to let him get his feet wet.
So we gave him a whole three months. That’s plenty of time to get a handle on a job he got through a presidential nomination to run a $5.3 billion operation, right? (He told me he’s still on his listening and learning tour.) After some back and forth, we settled on Jan. 24 as the day to do this.
Then the government shut down Saturday, Jan. 20.
And it remained shut down on Monday, Jan. 22. The NCI folks initially canceled, and with this schedule, there’s a good chance that a cancelation meant this interview wouldn’t have happened or I would have had to wait months. Fortunately, NCI’s press team was able to move forward as scheduled since the shutdown lasted only one business day.
Because it was so short, Sharpless told me this particular government shutdown wasn’t too disruptive and didn’t compromise the NCI’s mission of taking care of patients with cancer and easing the burden on patients with cancer. “Having said that, I hope to never go through this again.”
In this video and later off-camera but on the record, Sharpless discussed a wide range of topics from the “financial toxicity” that can stem from the high patient costs for cancer treatments—and what his institute can and can’t do about it—to data sharing, revamping on clinical trials, and why today’s researchers are poised do for cancer what Louis Pasteur and Robert Koch did for antibiotics and microbiomes.
You can read my story here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)